MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

NCT05903092 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

84

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer
SCLC
Extensive Stage Small Cell Lung Cancer
Limited Stage Small-Cell Lung Cancer

Interventions

DRUG: Durvalumab
DRUG: Monalizumab
DRUG: Carboplatin or Cisplatin
DRUG: Etoposide

Sponsor

Hirva Mamdani

Collaborators

[object Object]
[object Object]